drugset / Trial / NCT07015242
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Timeline
- Start
- 2025-11-06
- Primary completion
- 2028-01-09
- Completion
- 2028-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lisocabtagene Maraleucel | Cell therapy | — | — |
| Background | Calcium folinate | Unknown | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Temozolomide | Small molecule | — | — |
| Background | procarbazine | Small molecule | — | — |